Biontech Se Stock Investor Sentiment

BNTX Stock  USD 114.57  0.03  0.03%   
Slightly above 54% of BioNTech's investor base is interested to short. The analysis of the overall investor sentiment regarding BioNTech SE suggests that many traders are impartial. BioNTech's investing sentiment can be driven by a variety of factors including economic data, BioNTech's earnings reports, geopolitical events, and overall market trends.

Comfort Level 46

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioNTech's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioNTech SE.

BioNTech Historical Sentiment

Although BioNTech's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding BioNTech, such as negative comments on social media and news outlets, may cause fear in the market and push BioNTech's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of BioNTech.

BioNTech Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards BioNTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BioNTech SE Historical Investor Sentiment

Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average BioNTech news discussions. The higher the estimate score, the more favorable the investor's outlook on BioNTech.

BioNTech Maximum Pain Price Across September 19th 2025 Option Contracts

BioNTech's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of BioNTech close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of BioNTech's options.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of BioNTech's Stock prices. Below is the latest headlines and news related to BioNTech SE Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about BioNTech that are available to investors today. This information is accessible both publicly - through BioNTech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of BioNTech-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of BioNTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioNTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioNTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioNTech alpha.

BioNTech Largest EPS Surprises

Earnings surprises can significantly impact BioNTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-11-14
2019-09-30-0.16-0.130.0318 
2020-03-31
2019-12-31-0.17-0.26-0.0952 
2023-08-07
2023-06-30-0.96-0.790.1717 
2024-05-06
2024-03-31-1.17-1.41-0.2420 
2020-08-11
2020-06-30-0.06-0.38-0.32533 
2020-11-10
2020-09-30-0.37-0.88-0.51137 
View All Earnings Estimates
22 hours ago at news.google.com         
BioNTech price extends gains - Forecast today - 24-07-2025 - Economies.com
Google News at Macroaxis
3 days ago at news.google.com         
BioNTech SE to Release Second Quarter 2025 Financial Results and Host Conference Call on August 4, 2...
Google News at Macroaxis
few days ago at news.google.com         
What analysts say about BioNTech SE Depositary Receipt stock - High-velocity capital appreciation - ...
Google News at Macroaxis
few days ago at news.google.com         
What drives BioNTech SE Depositary Receipt stock price - Free Investment Risk Control - Jammu Links ...
Google News at Macroaxis
six days ago at news.google.com         
BioNTech CSO Exits After Driving 1B in Financing and Strategic Growth Key Leadership Change Details ...
Google News at Macroaxis
over a week ago at news.google.com         
BNTX BioNTech Stock Rating Maintained as Price Target Adjusted - GuruFocus
Google News at Macroaxis
over a week ago at news.google.com         
BioNTech More Uncertainty Emerges - Seeking Alpha
Google News at Macroaxis
over two weeks ago at news.google.com         
Recent Agreements Set To Bolster BioNTech SE s Oncology Arm - Insider Monkey
Google News at Macroaxis
over three weeks ago at news.google.com         
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
Google News at Macroaxis
over three weeks ago at news.google.com         
Truist Financial Remains a Buy on BioNTech SE - The Globe and Mail
Google News at Macroaxis
over three weeks ago at news.google.com         
BioNTech ADR Gets Relative Strength Rating Upgrade - Investors Business Daily
Google News at Macroaxis
over three weeks ago at news.google.com         
BioNTech Reports 415M Loss While Fast-Tracking Cancer Drug Development and Maintaining 15.9B Cash Po...
Google News at Macroaxis
over a month ago at news.google.com         
On The My Stocks Page - news.stocktradersdaily.com
Google News at Macroaxis
over a month ago at news.google.com         
CureVac Soars 41 percent in a Month on a 1.25B Buyout Offer From BioNTech - Zacks Investment Researc...
Google News at Macroaxis
over a month ago at news.google.com         
BioNTech SE Updates Articles of Association to Boost Financial Flexibility - TipRanks
Google News at Macroaxis
There is far too much social signal, news, headlines, and media speculation about BioNTech that are available to investors today. This information is accessible both publicly - through BioNTech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of BioNTech-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of BioNTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioNTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioNTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioNTech alpha.

BioNTech Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
BioNTech SE Q1 2025 Earnings Call Transcript
05/06/2025
2
Goldman Sachs Sets Neutral Rating for BioNTech with 110 Target BNTX Stock News
05/29/2025
3
Why BioNTech SE Skyrocketed On Monday
06/03/2025
4
BMY Collaborates for Oncology Drug Will This Boost Its Portfolio
06/06/2025
5
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To Restore Public Trust Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading
06/10/2025
6
All-stock deal BioNTech bags mRNA vaccine rival CureVac for 1.25bn - BioXconomy
06/16/2025
7
BioNTech More Uncertainty Emerges - Seeking Alpha
07/14/2025
8
BioNTech price extends gains - Forecast today - 24-07-2025 - Economies.com
07/24/2025

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.